Exalenz launches H pylori breath test in US
This article was originally published in Clinica
Executive Summary
Exalenz Bioscience (Modi'in, Israel) has launched its BreathID system in the US for detection of Helicobacter pylori. The point-of-care device, which detects the bacteria in around 10 minutes, analyses changes in carbon 13 and carbon 12 ratios in a patient's breath. H pylori can inhabit the human gastrointestinal tract, causing chronic low-level inflammation that can eventually cause peptic ulcers and stomach cancer. It can be treated with a combination of antibiotics and proton pump inhibitors. The test is the first that Exalenz has launched on its BreathID platform. Meanwhile, the company has also appointed Dennis Boyle vice-president and national manager in the US. Mr Boyle previously worked for Siemens USA.